Reagents and consumables will lead bleeding disorder testing sales through 2036 with 57.3% of the product type segment in 2026. The market was valued at USD 109.20 billion in 2025 and is expected to be worth USD 234.62 billion by 2036, creating an incremental opportunity of USD 117.56 billion.